Contrast-based imaging, including contrast-enhanced mammography (CEM) and magnetic resonance imaging (MRI), is not routinely used to locally stage patients diagnosed with screen-detected breast cancer.
However, it may improve local staging through identification of mammographically occult disease and may facilitate appropriate management of screen-detected breast cancers. Contrast-based imaging may also ultimately lead to improved oncological outcomes in screen-detected breast cancer.
With over 20-years’ experience, Prof Mann has successfully led several clinical trials, implementing new approaches to cancer care with evidence-based, best practice standards. He was central to the development of processes for tissue banking and data collection to enable translational breast cancer research. A leader in collaborative enterprise, he integrated the breast units of the Royal Melbourne Hospital with the Royal Women’s Hospital and was subsequently appointed Director of Breast Cancer Services, bringing the breast unit at Peter Mac together with the breast service at both hospitals. A major achievement is the implementation of a Clinical Research and Information Management System; delivering comprehensive and searchable data, routinely collected from all patients treated for early breast cancer.
Dr MacCallum qualified as a General Surgeon in 2022, with a special research interest in very early breast cancer, in particular the use of contrast breast imaging in diagnosis, staging, and formulation of appropriate treatment plans. She has presented this research in the US, Europe and Australia and will begin an Oncoplastic Breast Surgical Fellowship in Manchester, UK in August 2024.
